Switzerland· 62956006
Invokana
A canagliflozin product containing canagliflozinum, registered in Switzerland and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 15 of our 19 countries.
Checked against BAG Spezialitätenliste (Switzerland) on
Informational only — not a medical device.
Where it is registered
Canagliflozin is registered in 15 of 19 countries.
Countries holding a registration under ATC A10BK02 (canagliflozin), each read from that country’s own register.
- This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
- 9 of them publish a price we can compare per daily dose
Canagliflozin · ATC A10BK02
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of canagliflozin costs, country by country.
Normalised to the WHO defined daily dose (0.2 g), the median price runs from $2.52 in Switzerland to $25.50 in United States — a ×10 gap.
- Switzerland: $2.52 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Canagliflozin · price per daily dose (0.2 g)
USD · FX 28 Sept 2026
- US United States$25.50 (acquisition cost)
- IT Italy$3.76
- CH Switzerland$2.52
The record
At a glance
BAG Spezialitätenliste (Switzerland)- Active substance
- canagliflozinum
- Manufacturer
- —
- Country
- Switzerland (CH)
- ATC code
- A10BK02
- ATC class
- Canagliflozin
- Defined daily dose
- 0.2 g, O
- Swissmedic category
- B
- Reimbursed
- Yes
- Source register
- BAG Spezialitätenliste (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin768062956006730 StkCHF 68.8
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
429 interactions on record for canagliflozin.
Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Canagliflozin · interactions on record
429 records
- 1 severe
- 388 moderate
- 40 minor
Most severe, free to view
- SucralfateA02BX02moderate
- PapaverineA03AD01moderate
- ThiethylperazinA04AB03moderate
- TriflupromazinA04AD06moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Canagliflozin in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainCANAGLIFLOZINA TEVA 300 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGTeva B.V.
- United StatesINVOKANAA-S Medication Solutions
- CzechiaINVOKANAJanssen-Cilag International N.V., Beerse
- FinlandCanagliflozin ratiopharmTeva B.V.
- IcelandInvokanaJanssen-Cilag International NV*
- NetherlandsInvokana 300 mg filmomhulde tablettenJanssen-Cilag International NV
- NorwayInvokanaJanssen-Cilag International N.V
- PolandInvokanaJanssen-Cilag International N.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Invokana
- Liechtenstein · Invokana
- Norway · Invokana
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/aba5ba41-2f15-43cf-b3b8-c507b43bd76d GET /v1/drugs/aba5ba41-2f15-43cf-b3b8-c507b43bd76d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "canagliflozinum 300 mg",
"valid_from": "2014-03-01",
"limitations": "[{\"description\":\"<p>Zur Behandlung von erwachsenen Patienten mit einem Typ 2 Diabetes mellitus zur Verbesserung der glykämischen Kontrolle, wenn durch Diät und gesteigerte körperliche Aktivität keine ausreichende Kontrolle der Glykämie erreicht wird: <br>- Als Monotherapie bei Patienten, die nicht mit Metformin behandelt werden können. <br>- In Kombination mit:<br> - Metformin <br> - einem Sulfonylharnstoff <br> - einem DPP4-Inhibitor (mit oder ohne Metformin) <br> - einem GLP-1-Analogon (mit oder ohne Metformin) <br> - Insulin, alleine oder in Kombination mit Metformin und/oder Sulfonylharnstoff.</p>\\n<p> </p>\",\"costApproval\":null,\"indication\":\"20149.01\",\"isNew\":true,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2026-08-01\",\"validTo\":null}]",
"galenic_form": "Filmtabl 300 mg",
"therapeutic_area": null,
"sl_inclusion_date": "2014-03-01",
"self_retention_pct": 10
}See everything about canagliflozin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.